OPKO Health issues $125M notes to HealthCare Royalty
Analysis based on 6 articles · First reported Aug 13, 2026 · Last updated Aug 13, 2026
The transaction provides OPKO with $125 million in non-dilutive capital, improving its liquidity and financial flexibility, which is likely viewed positively by investors. For Healthcare Royalty and KKR, the deal expands their royalty investment portfolio, offering exposure to a high-growth segment in China, potentially enhancing their investment returns.
OPKO Health, Inc. announced on August 13, 2026, the expansion of its financing relationship with Healthcare Royalty (HCRx), a business of KKR, through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The notes are secured by OPKO's royalty interests from its mazdutide license agreement with Eli Lilly and Company and mature in 2044. The transaction provides OPKO with non-dilutive capital while preserving long-term royalty upside, with total payments capped at 1.5 times the amount funded. Mazdutide is being commercialized in China by Innovent Biologics, and OPKO recorded initial royalty revenue in 2025. The deal strengthens OPKO's balance sheet and demonstrates its ability to leverage royalty assets for financing.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard